Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antidepressant “Black Box” Warning For Pediatric Suicidality Risk Recommended

This article was originally published in The Pink Sheet Daily

Executive Summary

“Black box” warning would encourage discussion of risks and benefits of antidepressant therapy in children by physicians, FDA advisory committee members say. Warning likely to affect direct-to-consumer advertising, FDA notes. Committee members recommend class warning for all antidepressants, including new products.

You may also be interested in...



Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says

A committee will meet within the next few months to review selective serotonin reuptake inhibitors and suicidality in adults, J&J Senior VP Waldstreicher says. The company’s NDA for the SSRI dapoxetine is pending; J&J is seeking to differentiate the premature ejaculation agent from the rest of the class.

Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says

A committee will meet within the next few months to review selective serotonin reuptake inhibitors and suicidality in adults, J&J Senior VP Waldstreicher says. The company’s NDA for the SSRI dapoxetine is pending; J&J is seeking to differentiate the premature ejaculation agent from the rest of the class.

Antidepressant DTC Ads Must Disclose New Risk Information Within 30 Days

Antidepressant manufacturers have 30 days to bring their direct-to consumer ads into compliance following FDA's approval of a "black box" class warning

Related Content

Topics

UsernamePublicRestriction

Register

PS060542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel